The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer

expressing Gb3Injections of the B subunit of Shiga toxin 1 into HT29 human colon cancer cells engrafted into the flanks of nude mice inhibited tumor ...

O Kovbasnjuk，R Mourtazina，B Baibakov，... - 《Proceedings of the National Academy of Sciences of the United States of America》

An evolved ribosome-inactivating protein targets and kills human melanoma cells in vitro and in vivo

Background Few treatment options exist for patients with metastatic melanoma, resulting in poor prognosis. One standard treatment, dacarbazine (DTIC), show...

MC Cheung，L Revers，S Perampalam，... - 《Molecular Cancer》

Human breast cancer and lymph node metastases express Gb3 and can be targeted by STxB-vectorized chemotherapeutic compounds

Background The B-subunit of Shiga toxin (STxB) specifically binds to the glycosphingolipid Gb3 that is highly expressed on a number of human tumors and has...

L Stimmer，S Dehay，F Nemati，... - 《Bmc Cancer》

Abstract 868: HER2-targeted engineered toxin body demonstrates selective binding and cell kill of HER2-overexpressing breast cancer.

HER2 overexpression in breast cancer has been successfully targeted by both antibody and antibody-drug conjugate approaches. Trastuzumab, a humanized monoclonal antibody is approved for the treatment of HER2 positive metastatic breast cancer. ...

S Rajagopalan，E Willert，R Wirth，... - 《Cancer Research》

Abstract P4-08-18: Engineered Toxin Bodies Specific for TROP2 Positive Cancers

ETBs are comprised of a proprietarily engineered form of Shiga-like Toxin A subunit (SLT-A) genetically fused to antibody-like binding domains. ETBs work through novel mechanisms of action and are capable of forced internalization, ...

GL Cornelison，I Pedraza，K Garrison，... - 《Cancer Research》

Bevacizumab-Associated Thrombotic Microangiopathy Treated with Eculizumab: A Case Report

Objective: Rare disease Background: Bevacizumab is an approved targeted therapy for metastatic cancer treatment. It can have adverse effects on multiple or...

WS Carvalho Padilha，B Nogueira Cesar，S Theodoro Pacheco，... - 《American Journal of Case Reports》

Abstract 326: Engineered toxin bodies (ETBs) targeting Trop2

Engineered toxin bodies (ETBs) are comprised of a proprietarily engineered form of Shiga-like Toxin A subunit (SLT-A) genetically fused to antibody-like binding domains. ETBs work through novel mechanisms of action and are capable of for...

GL Cornelison，A Bartos，B Brieschke，... - 《Cancer Research》

First-in-human dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relap...

Background: MT-6402 is a unique and potent PD-L1-targeted engineered toxin body (ETB) capable of directly killing PD-L1 expressing tumor and immune cells b...

ER Ahn，HL Duvivier，DW Rasco，... - 《Journal of Clinical Oncology》